28 Oct How Immunotherapy Is Changing Breast Cancer Treatment in the UAE
Cancer Care Notice: Immunotherapy is approved only for specific types and stages of breast cancer, and results described here reflect averages across groups of patients in clinical trials, not guarantees for any individual. Some uses discussed are still being studied. Treatment decisions should be made with your oncology team. If you are receiving immunotherapy, report new symptoms such as cough or shortness of breath, diarrhea, severe fatigue, rash, or yellowing of the skin or eyes to your care team promptly, as immune-related side effects can be serious.
Editorial Notice: This article is for general information and is not specific medical advice. Hospitals and providers named or linked in this article are not warranted or endorsed by MedicalResearch.com or Eminent Domains Inc.
Breast cancer remains the most commonly diagnosed cancer among women in the United Arab Emirates, accounting for nearly 40 percent of all female cancer cases, according to national registry data. While traditional treatments like chemotherapy, radiation, and surgery have long formed the backbone of care, a newer approach is reshaping outcomes for certain patients: immunotherapy. This treatment harnesses the body's immune system to recognize and attack cancer cells, offering hope particularly for aggressive subtypes that have historically been difficult to treat.
The shift toward immunotherapy reflects a broader transformation in oncology, where precision medicine tailors treatment to the specific characteristics of each tumor. For breast cancer patients in Abu Dhabi and across the UAE, understanding how immunotherapy works, who benefits most, and how it fits into comprehensive care can inform better treatment decisions.